IATDMCT Congress 2017 Oral Presentations

Session	Session title	Program No.	Title	Speaker	Institution	Country
O27-4	Oncology (2)	O27-4-1	Therapeutic drug monitoring (TDM) approaches for the treatment of neonates and children with cancer: a UK experience	Gareth James Veal	Newcastle University	United Kingdom
		O27-4-2	Population pharmacokinetic modeling of alemtuzumab in pediatric patients undergoing allogeneic hematopoietic cell transplantation for non-malignant diseases	,	Cincinnati Children's Hospital Medical Center	United States of America
		O27-4-3	The Effects of Advanced Age and Serum alpha1-Acid Glycoprotein on Docetaxel Unbound Exposure and Dose-limiting Toxicity in Cancer Patients	Hirotsugu Kenmotsu	Shizuoka Cancer Center	Japan
		O27-4-4	UGT1A1 polymorphism may be a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan	Tomoko Yoshihama	Keio University	Japan